Evaluation Of Eslicarbazepine In The Management Of Partial Seizures
Pharmaceutical Marketing in India
Versandkostenfrei!
Versandfertig in 6-10 Tagen
36,99 €
inkl. MwSt.
PAYBACK Punkte
18 °P sammeln!
Eslicarbazepine is a novel adds on therapy introduced in Indian market in April 2011 in the management of partial seizures. Despite of having a strong pool of evidences & EMEA approval, this molecule in-clinic usage is not as per expectations. Through this research work, we intend to make an attempt to understand underlying psychological & environmental (peer group effect) factors restricting the potential of molecule. The major emphasize of my work was to "EVALUATION OF IN - CLINIC USAGE OF ESLICARBAZEPINE IN THE MANAGEMENT OF PARTIAL SEIZURES" This project gave me immense opportunities to up...
Eslicarbazepine is a novel adds on therapy introduced in Indian market in April 2011 in the management of partial seizures. Despite of having a strong pool of evidences & EMEA approval, this molecule in-clinic usage is not as per expectations. Through this research work, we intend to make an attempt to understand underlying psychological & environmental (peer group effect) factors restricting the potential of molecule. The major emphasize of my work was to "EVALUATION OF IN - CLINIC USAGE OF ESLICARBAZEPINE IN THE MANAGEMENT OF PARTIAL SEIZURES" This project gave me immense opportunities to upgrade my knowledge related to marketing field and also gave me a chance to learn and understand the strategies to be kept in mind while making a new molecule for AED's.
Andere Kunden interessierten sich für
